|
|
News Breaks | | | | October 12, 2012 | | 08:06 EDT |  | VRTX | Vertex shares attractive, says ThinkEquity
After Vertex presented key efficacy and safety data for VX809 combination therapy, ThinkEquity believes that the data suggests that the therapy is providing a clinical benefit. The firm thinks that this benefit could be replicated in a Phase III study and it suggests owning the stock. ThinkEquity maintains a Buy rating on the shares. | |
|
News For VRTX From The Last 14 Days Check below for free stories on VRTX the last two weeks. |
|
|
| May 10, 2013 | | 14:02 EDT | | VRTX | Vertex to benefit from Welsh government decision, says Wells Fargo
 Subscribe for More Information | |
|
|
|
|
|
|
